Savara Inc. (SVRA)
NASDAQ: SVRA · IEX Real-Time Price · USD
4.470
-0.240 (-5.10%)
At close: Jul 19, 2024, 4:00 PM
4.420
-0.050 (-1.12%)
Pre-market: Jul 22, 2024, 8:42 AM EDT
Savara Employees
Savara had 37 employees as of December 31, 2023. The number of employees increased by 9 or 32.14% compared to the previous year.
Employees
37
Change (1Y)
9
Growth (1Y)
32.14%
Revenue / Employee
n/a
Profits / Employee
-$1,742,892
Market Cap
735.03M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Sage Therapeutics | 487 |
Travere Therapeutics | 380 |
Lexicon Pharmaceuticals | 285 |
Wave Life Sciences | 268 |
Pliant Therapeutics | 158 |
4D Molecular Therapeutics | 147 |
CARGO Therapeutics | 116 |
Stoke Therapeutics | 110 |
SVRA News
- 24 days ago - Savara Announces Pricing of $100.0 Million Underwritten Offering of Common Stock - Business Wire
- 25 days ago - Why Is Respiratory Disease-Focused Savara Stock Trading Higher On Wednesday? - Benzinga
- 26 days ago - Savara's rare lung disease drug meets main goal in late-stage study - Reuters
- 26 days ago - Savara Announces Molgramostim Nebulizer Solution (Molgramostim) Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2, a Pivotal Phase 3 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) - Business Wire
- 26 days ago - Savara to Host Investor Call to Discuss Top Line Results From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) - Business Wire
- 7 weeks ago - Savara to Present at the Jefferies Global Healthcare Conference - Business Wire
- 2 months ago - Savara Presented New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024 - Business Wire
- 2 months ago - Savara Announces New Employment Inducement Grant - Business Wire